Connor, Clark & Lunn Investment Management (CC&L)’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-290,595
| Closed | -$1.7M | – | 1516 |
|
|
2022
Q4 | $1.7M | Sell |
290,595
-9,763
| -3% | -$51.3K | 0.01% | 586 |
|
|
2022
Q3 | $2.01M | Hold |
300,358
| – | – | 0.01% | 494 |
|
|
2022
Q2 | $1.26M | Sell |
300,358
-33,400
| -10% | -$132K | 0.01% | 567 |
|
|
2022
Q1 | $1.13M | Sell |
333,758
-1,287
| -0.4% | -$4.08K | 0.01% | 637 |
|
|
2021
Q4 | $1.05M | Sell |
335,045
-4,792
| -1% | -$15.9K | 0.01% | 668 |
|
|
2021
Q3 | $1.11M | Sell |
339,837
-1,506
| -0.4% | -$5.28K | 0.01% | 626 |
|
|
2021
Q2 | $1.44M | Hold |
341,343
| – | – | 0.01% | 611 |
|
|
2021
Q1 | $1.7M | Sell |
341,343
-112
| -0% | -$905 | 0.01% | 597 |
|
|
2020
Q4 | $4.32M | Sell |
341,455
-2,596
| -0.8% | -$29.6K | 0.03% | 372 |
|
|
2020
Q3 | $3.38M | Sell |
344,051
-7,969
| -2% | -$78.5K | 0.02% | 374 |
|
|
2020
Q2 | $3.5M | Sell |
352,020
-12,524
| -3% | -$120K | 0.02% | 360 |
|
|
2020
Q1 | $3.22M | Sell |
364,544
-8,575
| -2% | -$84.6K | 0.03% | 322 |
|
|
2019
Q4 | $3.44M | Hold |
373,119
| – | – | 0.02% | 332 |
|
|
2019
Q3 | $2.19M | Sell |
373,119
-11,350
| -3% | -$120K | 0.02% | 394 |
|
|
2019
Q2 | $4.61M | Sell |
384,469
-17,060
| -4% | -$183K | 0.03% | 302 |
|
|
2019
Q1 | $4.85M | Sell |
401,529
-19,881
| -5% | -$293K | 0.03% | 282 |
|
|
2018
Q4 | $5.29M | Sell |
421,410
-35,224
| -8% | -$486K | 0.04% | 260 |
|
|
2018
Q3 | $6.78M | Buy |
456,634
+43,512
| +11% | +$685K | 0.04% | 270 |
|
|
2018
Q2 | $6.95M | Buy |
413,122
+82,922
| +25% | +$1.61M | 0.04% | 261 |
|
|
2018
Q1 | $7.56M | Buy |
330,200
+230,675
| +232% | +$5.13M | 0.05% | 233 |
|
|
2017
Q4 | $2.58M | Buy |
+99,525
| New | +$2M | 0.02% | 392 |
|
|
2016
Q1 | – | Sell |
-21,200
| Closed | -$402K | – | 920 |
|
|
2015
Q4 | $402K | Sell |
21,200
-10,500
| -33% | -$228K | ﹤0.01% | 583 |
|
|
2015
Q3 | $595K | Buy |
31,700
+4,800
| +18% | +$81.6K | ﹤0.01% | 493 |
|
|
2015
Q2 | $401K | Buy |
26,900
+1,900
| +8% | +$28.9K | ﹤0.01% | 455 |
|
|
2015
Q1 | $379K | Buy |
25,000
+11,500
| +85% | +$160K | ﹤0.01% | 429 |
|
|
2014
Q4 | $180K | Buy |
+13,500
| New | +$174K | ﹤0.01% | 534 |
|
Connor, Clark & Lunn Investment Management (CC&L)'s CNCE Position: Q1 2023 in Review
Connor, Clark & Lunn Investment Management (CC&L) sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 290,595 shares — an estimated $1.7M sold.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CNCE in Q4 2014 and held it in 26 quarters. The position peaked at $7.56M in Q1 2018. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Connor, Clark & Lunn Investment Management (CC&L) sold 290,595 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $1.7M.
- Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Concert Pharmaceuticals, Inc. in Q4 2014 and held it in 26 quarters.
- Connor, Clark & Lunn Investment Management (CC&L)'s Concert Pharmaceuticals, Inc. position peaked at $7.56M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2023, filed 10 May 2023.